Recent news highlights Polaryx’s preparations for initiating the SOTERIA Phase 2 basket trial in the first half of 2026 and presentation of late-breaker data related to SOTERIA at a major symposium.

• Polaryx announced plans to initiate the SOTERIA Phase 2 basket trial in the first half of 2026, a multi-indication study targeting several LSDs including CLN2, CLN3, Krabbe disease, and Sandhoff disease [N1].
• The company presented late-breaker data related to the SOTERIA trial at the 22nd Annual WORLDSymposium™, indicating progress in preparing for the trial launch [N2].

Polaryx’s lead candidate PLX-200 targets multiple rare LSDs with significant unmet needs, supported by orphan drug and fast track designations. The planned Phase 2 SOTERIA basket trial is designed to efficiently assess safety and clinical activity across several indications, potentially enabling streamlined development and regulatory pathways. The proprietary pediatric oral solution formulation addresses compliance challenges in pediatric patients. The company’s multi-modal pipeline, including small molecules and gene therapy, offers a comprehensive approach to LSD treatment. Strong liquidity ratios as of end 2025 provide runway for near-term clinical activities. Operational support from experienced management and Mstone Partners enhances execution capabilities.

Polaryx faces substantial risks including dependence on the success of PLX-200, which if unsuccessful could adversely impact the entire small molecule portfolio. The company has no approved products and has incurred significant net losses, with an accumulated deficit nearing $100 million as of end 2025. Clinical development is subject to delays, regulatory uncertainties, and potential manufacturing challenges due to reliance on third-party CMOs. The company requires additional capital to fund ongoing operations and clinical trials, with substantial doubt about its ability to continue as a going concern noted in filings. The rarity and complexity of LSDs pose challenges in patient recruitment and trial design, and reimbursement and market adoption remain uncertain.

Polaryx’s moat is based on its focus on rare pediatric lysosomal storage disorders with high unmet medical need, leveraging a multi-modal therapeutic approach combining small molecule and gene therapies. Its lead candidate, PLX-200, benefits from orphan drug and fast track designations, a proprietary pediatric oral formulation, and a regulatory pathway (505(b)(2)) that may reduce development time and cost by referencing existing safety data. The company’s pipeline shares common mechanisms of action targeting lysosomal biogenesis, neuroinflammation, and neuronal survival, potentially enabling treatment across multiple LSD indications. Strategic partnerships and licensing agreements, including with Rush University Medical Center and operational support from Mstone Partners, provide additional resources and expertise. However, the company’s moat is contingent on successful clinical development and regulatory approval, with significant risks inherent in early-stage biotech.

• Dependence on PLX-200: The company is substantially dependent on the success of its lead drug candidate PLX-200. Failure in clinical trials or regulatory approval could significantly harm the development prospects of PLX-200 and related pipeline candidates.
• Clinical and Regulatory Risks: Clinical trials may face delays, failures, or safety issues. Regulatory approval processes are lengthy, unpredictable, and may require additional studies or data.
• Financial and Liquidity Risks: Polaryx has incurred significant losses and has an accumulated deficit. It requires substantial additional capital to fund operations and clinical development. There is substantial doubt about its ability to continue as a going concern without additional funding.
• Manufacturing and Supply Risks: The company relies on third-party contract manufacturing organizations (CMOs) for drug production. Any disruption or failure in supply could delay development timelines.
• Market and Commercialization Risks: No products are approved for sale. The company has not established commercial manufacturing, sales, or distribution capabilities. Market acceptance and reimbursement for therapies targeting rare LSDs are uncertain.

• Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs).
• The company’s therapeutic approach integrates small molecule therapies, including combination therapy, and gene therapy to address genetic and downstream pathological features of LSDs.
• Their lead drug candidate is PLX-200 (gemfibrozil), an oral small molecule reformulated for pediatric use via a proprietary oral solution, being developed through the FDA 505(b)(2) regulatory pathway.
• PLX-200 targets multiple LSDs including CLN2 and CLN3 subtypes of neuronal ceroid lipofuscinosis (NCLs), Krabbe disease, and Sandhoff disease, representing about one quarter of the LSD population.
• Polaryx plans to initiate a Phase 2 proof-of-concept basket trial called SOTERIA in the second half of 2026, which is an open-label, multi-indication master study to assess safety, tolerability, and clinical activity of PLX-200.
• The company submitted an IND application for SOTERIA in August 2025 and received FDA clearance to proceed in October 2025.
• PLX-200 has received three orphan drug designations (ODD) for NCLs, GM2 gangliosidoses, and Krabbe disease, and fast track designation for CLN2 and CLN3 indications.
• Other pipeline candidates include PLX-300 (cinnamic acid), in IND-enabling studies with orphan drug and rare pediatric drug designations, PLX-100 (combination therapy of PLX-200 and vitamin A) in preclinical stage with orphan drug designation, and PLX-400, a preclinical gene therapy candidate.
• The company’s small molecule candidates share modes of action involving PPARα-dependent upregulation of TFEB, enhancing lysosomal biogenesis, reducing neuroinflammation, and promoting neuronal survival.
• Polaryx was founded in 2014, redomesticated to Nevada in 2025, and has raised $21.7 million from institutional and private investors.
• The company outsources manufacturing to third-party CMOs and currently has no commercial manufacturing facilities.
• Polaryx has no products approved for commercial sale and has incurred significant net losses since inception, including a net loss of approximately $9.0 million for the year ended December 31, 2025.
• As of December 31, 2025, the company had cash and cash equivalents of $5.14 million, current assets of $5.17 million, current liabilities of $0.605 million, resulting in a current ratio of 8.55 and a cash ratio of 8.5, indicating strong liquidity.
• The company’s accumulated deficit was approximately $99.6 million as of December 31, 2025.
• Polaryx’s management team includes experienced executives with expertise in rare and orphan disease drug development, supported by operational services from controlling stockholder Mstone Partners Healthcare Limited.
• The company’s strategy focuses on advancing PLX-200 through the SOTERIA trial, optimizing potentially pivotal trials for CLN2 and CLN3, pursuing approval via the 505(b)(2) pathway, and expanding the pipeline and indications.
• The SOTERIA trial design includes natural history data as a control arm for CLN2 and CLN3 cohorts and aims to provide data to guide registrational trials and potential accelerated approval.
• The company faces risks including dependence on PLX-200’s success, clinical trial uncertainties, regulatory approval challenges, manufacturing reliance on third parties, and the need for additional capital to fund operations.